分化型甲状腺癌术后患者血清Cyfra21.1、Gal-3、VEGF水平及其意义

彭一帆; 山院飞; 赵胤铭; 张瑞明

doi:10.13406/j.cnki.cyxb.000768

您当前的位置：

首页 >

文章列表页 >

分化型甲状腺癌术后患者血清Cyfra21.1、Gal-3、VEGF水平及其意义

肿瘤诊断与治疗 | 更新时间：2024-01-17

- 分化型甲状腺癌术后患者血清Cyfra21.1、Gal-3、VEGF水平及其意义
- Serum levels of Cyfra 21.1,galectin-3 and VEGF in patients with differentiated thyroid carcinoma after surgery
- 重庆医科大学学报 2015年40卷第11期页码：1441-1444
- 作者机构：
  
  1. 天津市环湖医院编辑部
  2. 空军航空医学研究所附属医院普外科
  3. 内蒙古医科大学附属医院普外科
- 作者简介：
- 基金信息：
- DOI：10.13406/j.cnki.cyxb.000768
  中图分类号： R736.1
- 纸质出版日期：2015，
扫描看全文
[1]彭一帆,山院飞,赵胤铭,张瑞明.分化型甲状腺癌术后患者血清Cyfra21.1、Gal-3、VEGF水平及其意义[J].重庆医科大学学报,2015,40(11):1441-1444.

Peng Yifan, Shan Yuanfei, Zhao Yinming, et al. Serum levels of Cyfra 21.1,galectin-3 and VEGF in patients with differentiated thyroid carcinoma after surgery[J]. Journal of Chongqing Medical University, 2015,40(11):1441-1444.
[1]彭一帆,山院飞,赵胤铭,张瑞明.分化型甲状腺癌术后患者血清Cyfra21.1、Gal-3、VEGF水平及其意义[J].重庆医科大学学报,2015,40(11):1441-1444. DOI： 10.13406/j.cnki.cyxb.000768.

Peng Yifan, Shan Yuanfei, Zhao Yinming, et al. Serum levels of Cyfra 21.1,galectin-3 and VEGF in patients with differentiated thyroid carcinoma after surgery[J]. Journal of Chongqing Medical University, 2015,40(11):1441-1444. DOI： 10.13406/j.cnki.cyxb.000768.

摘要

目的:探讨分化型甲状腺癌术后患者血清中细胞角蛋白19片段（cytokeratinfragment antigen 21.1

Cyfra 21.1）、半乳糖血凝素-3（galectin-3

Gal-3）、血管内皮生长因子（vascular endothelial growth factor

VEGF）的表达水平及意义。方法:收集内蒙古医科大学附属医院分化型甲状腺癌术后患者75例（未复发40例、局部复发35例）

甲状腺良性疾病术后患者30例（甲状腺腺瘤10例、结节性甲状腺肿20例）

采用化学发光法（chemi Luminescence

CLIA）、酶联免疫吸附法（enzyme-linked immuno sorbent assay

ELISA）检测其血清Cyfra 21.1、Gal-3、VEGF浓度。结果:血清Cyfra 21.1、Gal-3水平在各组间无明显差异（F=1.425、P=0.245;F=1.503、P=0.227）。甲癌术后局部复发组血清VEGF水平较未复发组有所增高（F=8.859、P=0.000）。结论:Cyfra 21.1、Gal-3血清水平暂不能用于甲状腺癌术后随访。血清VEGF水平可作为评估分化型甲状腺癌生物学行为的一项重要指标。

Abstract

Objective:To investigate the serum levels of cytokeratinfragment antigen 21.1(Cyfra 21.1)

galectin-3(Gal-3)

vascular endothelial growth factor(VEGF)in patients with differentiated thyroid carcinoma after surgery and to explore their clinical significances.Methods:Serum samples were collected from 75 patients with differentiated thyroid carcinoma after surgery(35 with regional recurrence

40 without recurrence)and 30 benign disease subjects(10 thyroid adenoma

20 nodular goiter). Cyfra 21.1

Gal-3

VEGF levels were detected using CLIA and ELISA. Results:Low Cyfra 21.1 and Gal-3 values were found in all subgroups

without significant differences(F=1.425

P=0.245;F=1.503

P=0.227). VEGF was significantly higher in patients with regional recurrence than in patients without recurrence and normal subjects(P=0.000). Conclusion:The serum levels of Cyfra 21.1 and Gal-3 could not be used as reliable markers for prognostic in patients after thyroidectomy. Serum VEGF is significantly elevated in differentiated thyroid carcinoma patients with postoperative recurrence

making it an important indicator to reveal the biological behaviors of differentiated thyroid carcinoma.

关键词

细胞角蛋白19片段半乳糖血凝素-3血管内皮生长因子甲状腺癌血清

Keywords

cytokeratinfragment antigen 21.1galectin-3vascular endothelial growth factorthyroid carcinomahuman serum

references

浏览量

125

下载量

CSCD

文章被引用时，请邮件提醒。

提交

工具集

关联资源

瑞芬太尼对椎间盘退变模型大鼠椎间盘的影响及机制

脑小血管病认知障碍与血清VEGF及PEDF的相关性研究

双下肢远端缺血后适应减轻SD大鼠脑缺血再灌注损伤及相关VEGF、MMP-9表达的影响

姜黄素通过下调VEGF的表达抑制髓母细胞瘤Daoy细胞增殖的作用研究

低强度超声对大鼠牙槽骨改建过程中血管内皮生长因子表达的影响